GH Research Announces Closing of $125 Million Oversubscribed Series B Financing Post published:April 12, 2021 Post category:Press Release
Psychedelic Bulletin: CA Decrim. Bill Passes Key Committee; MindMed Publishes MDMA Dosing Study; atai Acquires DTx Company Post published:April 9, 2021 Post category:Psychedelic Bulletin
Former FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory Advisor Post published:April 8, 2021 Post category:Press Release
MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors Post published:April 8, 2021 Post category:Press Release
Psychedelic Research Bulletin: March 2021 Post published:April 7, 2021 Post category:Psychedelics Research Review
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders Post published:April 7, 2021 Post category:Press Release
Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology Post published:April 7, 2021 Post category:Press Release
Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical Post published:April 7, 2021 Post category:Press Release
Lobe Sciences Appoints Ilan Hayman to Advisory Board Post published:April 6, 2021 Post category:Press Release
Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test Post published:April 6, 2021 Post category:Press Release